M&T Bank Corp Grows Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• M&T Bank Corp raised its stake in Boston Scientific by 27.5% in Q4 to 103,113 shares (an additional 22,214 shares), valuing the holding at about $9.83 million.
• Boston Scientific slightly beat quarterly estimates with $0.80 EPS vs. $0.79 and $5.20 billion in revenue (up 11.6% YoY), and issued Q2 2026 guidance of $0.82–0.84 and FY2026 guidance of $3.34–3.41 EPS.
• The stock trades near its 12‑month low (~$55.98 open), has a market cap of $83.2 billion and a P/E of 23.4, and carries a Wall Street consensus of "Moderate Buy" with an average target price of $93.91.

M&T Bank Corp lifted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 27.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,113 shares of the medical equipment provider's stock after purchasing an additional 22,214 shares during the period. M&T Bank Corp's holdings in Boston Scientific were worth $9,833,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Murphy & Mullick Capital Management Corp lifted its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. United Community Bank lifted its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 147 shares during the last quarter. Colonial Trust Co SC lifted its position in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 231 shares during the last quarter. Finally, Bangor Savings Bank lifted its position in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 142 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $55.98 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.08 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $55.88 and a twelve month high of $109.50. The stock has a 50 day moving average of $66.69 and a two-hundred day moving average of $84.28. The stock has a market cap of $83.20 billion, a P/E ratio of 23.42, a P/E/G ratio of 1.04 and a beta of 0.62.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. During the same quarter in the previous year, the business earned $0.75 earnings per share. The firm's revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BSX. The Goldman Sachs Group reduced their price objective on shares of Boston Scientific from $87.00 to $84.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $105.00 to $100.00 and set an "outperform" rating for the company in a research report on Thursday, April 23rd. Truist Financial reduced their price objective on shares of Boston Scientific from $90.00 to $85.00 and set a "buy" rating for the company in a research report on Thursday, April 23rd. Evercore reduced their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an "outperform" rating for the company in a research report on Thursday, February 5th. Finally, Wall Street Zen downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $93.91.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.